Table 3 Demographic and clinical characteristics of patients who started treatment with dose reduction
Demographic characteristics | ||
Age, n (%) | (n = 68) | |
< 65 years | 33 (48.5%) | |
65–79 years | 14 (20.6%) | |
≥ 70 years | 21 (30.9%) | |
Sex, n (%) | (n = 68) | |
Males | 41 (60.3%) | |
Females | 27 (39.7%) | |
Clinical characteristics | ||
Weight loss > 10%, n (%) | (n = 66) | 18 (27.3%) |
ECOG PS, n (%) | (n = 62) | |
0–1 | 46 (74.2%) | |
2-Mar | 16 (25.8%) | |
Karnofsky PS, n (%) | (n = 23) | |
< 70 | – | |
70–80 | 13 (56.5%) | |
90–100 | 10 (43.5%) | |
Common comorbidities, n (%) | (n = 68) | |
Hypertension | 15 (22.1%) | |
Diabetes | 8 (11.8%) | |
Dyslipemia | 4 (5.9%) | |
Hepatobiliary stent, n (%) | (n = 68) | 10 (14.7%) |
Platelet count, median (IR) | (n = 57) | 252.0 (172.0, 339.0) |
Bilirubin (mg/dL), median (IR) | (n = 58) | 0.70 (0.51, 1.10) |
NLR, n (%) | (n = 55) | |
> 3 | 29 (52.7%) | |
≤ 3 | 26 (47.3%) | |
CA 19.9, n (%) | (n = 62) | |
> 35 | 52 (83.9%) | |
≤ 35 | 10 (16.1%) | |
Number of metastatic sites, n (%) | (n = 68) | |
1–3 | 67 (98.5%) | |
> 3 | 1 (1.5%) | |
Concommitant treatment, n (%) | (n = 68) | |
Analgesics | 22 (32.4%) | |
Corticosteroids | 9 (13.2%) | |